News Story Headlines
October 27, 2022
WebMD Education
The ABCs of Amyloidosis: The Journey From Diagnosis to Treatment
This article is for people who have amyloidosis, or anyone who wants to learn more about this disease. The goal...
October 27, 2022
Subcutaneous Daratumumab Plus CyBorD Improves Outcomes in AL Amyloidosis
Raymond Comenzo, MD, Tufts Medical Center, Boston, Massachusetts, discusses results from the ANDROMEDA trial, which showed superiority with the addition of daratumumab to CyBorD over CyBorD alone for patients with...
October 27, 2022
Jonathan Wall receives $1.79 million to develop amyloidosis treatment
By BIOENGINEER – March 16, 2021
Memphis, Tenn. (March 16, 2021) – The National Institute of Diabetes and Digestive and Kidney Diseases recently awarded Jonathan Wall, PhD, professor in the...
October 27, 2022
October 10, 2022
Alnylam Reports Positive Topline 18-Month Results from HELIOS-A Phase 3 Study of Vutrisiran in Patients with hATTR Amyloidosis with Polyneuropathy
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Oct. 27, 2021– Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the HELIOS-A Phase 3 study of vutrisiran, an investigational...